Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)
- 4 April 2017
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 28 (7), 1554-1559
- https://doi.org/10.1093/annonc/mdx163
Abstract
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive disease. In this study, we report our experience from 119 patients with T-PLL. We reviewed the clinico-pathologic records of 119 consecutive patients with T-PLL, who presented to our institution between 1990 and 2016. One hundred and nineteen patients with T-PLL were analysed. Complex karyotype and aberrations in chromosome 14 were seen in 65% and 52% patients, respectively. Seventy-five patients (63%) were previously untreated and 43 (37%) were initially treated outside our institution. Sixty-three previously untreated patients (84%) received frontline therapies. Overall, 95 patients (80%) have died. Median overall survival (OS) from diagnosis was 19 months [95% confidence interval (CI) 16–26 months]. Using recursive partitioning (RP), we found that patients with hemoglobin < 9.3 g/dl, lactate dehydrogenase (LDH) ≥ 1668 IU/l, white blood cell ≥ 208 K/l and β2M ≥ 8 mg/l had significantly inferior OS and patients with hemoglobin < 9.3 g/dl had inferior progression-free survival (PFS). In multivariate analysis, we identified that presence of pleural effusion [hazard ratio (HR) 2.08 (95% CI 1.11–3.9); P = 0.02], high LDH (≥ 1668 IU/l) [HR 2.5 (95% CI 1.20–4.24); P < 0.001)], and low hemoglobin (< 9.3 g/dl) [HR 0.33 (95% CI 0.14–0.75); P = 0.008] were associated with shorter OS. Fifty-five previously untreated patients received treatment with an alemtuzumab-based regimen (42 monotherapy and 13 combination with pentostatin). Overall response rate, complete remission rate (CR) for single-agent alemtuzumab and alemtuzumab combined with pentostatin were 83%, 66% and 82%, 73% respectively. In patients who achieved initial CR, stem cell transplantation was not associated with longer PFS and OS. Outcomes in T-PLL remain poor. Multicenter collaborative effort is required to conduct prospective studies.Keywords
Funding Information
- National Institutes of Health
- National Cancer Institute (P01 CA049639)
This publication has 40 references indexed in Scilit:
- Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T‐cell prolymphocytic leukemiaCancer, 2013
- Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden ConsortiumLeukemia, 2011
- Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous routeBlood, 2011
- Array comparative genomic hybridization in the detection of chromosomal abnormalities in T-cell prolymphocytic leukemiaCancer Genetics and Cytogenetics, 2010
- Stem cell transplantation after alemtuzumab in T‐cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective studyBritish Journal of Haematology, 2010
- Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell NeoplasmsJournal of Clinical Oncology, 2009
- High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemiaBlood, 2008
- Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remissionBone Marrow Transplantation, 2006
- Structural Basis for the Co-activation of Protein Kinase B by T-cell Leukemia-1 (TCL1) Family Proto-oncoproteinsPublished by Elsevier BV ,2004
- A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemiaGenes, Chromosomes and Cancer, 2001